Axial Biotech hires VP for reimbursement and regulatory affairs
This article was originally published in Clinica
Rina Wolf has joined Axial Biotech (Salt Lake City, Utah), a firm specialising in diagnostic tests and implants for spinal conditions, as its vice-president of reimbursement and regulatory affairs. Her primary remit will be to achieve appropriate levels of insurance for the firm’s products. Ms Wolf joins from RedPath Integrated Pathology (cancer diagnostics) where she served in the same capacity. She has broad experience in the field and CEO of Axial John Climaco described Ms Wolf’s knowledge of molecular diagnostics regulations as “second to none”.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.